Profile data is unavailable for this security.
About the company
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
- Revenue in USD (TTM)382.81m
- Net income in USD68.13m
- Incorporated2006
- Employees624.00
- LocationADMA Biologics Inc465 State Route 17RAMSEY 07446United StatesUSA
- Phone+1 (201) 478-5552
- Fax+1 (201) 478-5553
- Websitehttps://www.admabiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.31bn | 988.00 | -- | -- | -- | 3.67 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.45bn | 702.00 | -- | 14.29 | -- | 4.83 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.69bn | 9.14k | -- | 0.8096 | 20.01 | 0.8412 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Organon & Co | 6.41bn | 1.30bn | 3.83bn | 10.00k | 2.95 | 7.78 | 2.46 | 0.5983 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 4.16bn | 570.00 | 20.50 | 2.40 | 17.50 | 3.74 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| BridgeBio Pharma Inc | 217.77m | -438.86m | 4.37bn | 550.00 | -- | -- | -- | 20.07 | -2.41 | -2.41 | 1.19 | -6.51 | 0.33 | -- | -- | 395,936.40 | -67.62 | -72.44 | -85.06 | -89.72 | 98.90 | 94.41 | -204.94 | -1,225.66 | -- | -9.40 | 3.43 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Axsome Therapeutics Inc | 338.46m | -310.96m | 4.71bn | 545.00 | -- | 51.20 | -- | 13.93 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| ADMA Biologics Inc | 382.81m | 68.13m | 5.04bn | 624.00 | 77.08 | 21.71 | 65.95 | 13.15 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.12m | -280.49m | 5.08bn | 253.00 | -- | 3.37 | -- | 501.91 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 5.81bn | 373.00 | 15.12 | 12.84 | 12.26 | 6.14 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Corcept Therapeutics Incorporated | 628.56m | 141.82m | 5.86bn | 352.00 | 44.04 | 9.14 | 40.98 | 9.32 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Elanco Animal Health Inc | 4.45bn | 205.00m | 6.62bn | 9.30k | 32.79 | 1.02 | 7.58 | 1.49 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Data as of Nov 21 2024. Currency figures normalised to ADMA Biologics Inc's reporting currency: US Dollar USD
45.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 34.75m | 14.91% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 17.48m | 7.50% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 13.00m | 5.58% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 10.61m | 4.55% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 5.47m | 2.35% |
| Geode Capital Management LLCas of 30 Sep 2024 | 5.38m | 2.31% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 5.26m | 2.26% |
| Two Sigma Advisers LPas of 30 Sep 2024 | 4.45m | 1.91% |
| AWM Investment Co., Inc.as of 30 Sep 2024 | 4.45m | 1.91% |
| American Century Investment Management, Inc.as of 30 Sep 2024 | 4.21m | 1.81% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
